Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) EPS (Basic) (2022 - 2025)

Historic EPS (Basic) for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$0.32.

  • Atara Biotherapeutics' EPS (Basic) rose 8907.85% to -$0.32 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.34, marking a year-over-year increase of 11304.69%. This contributed to the annual value of -$11.41 for FY2024, which is 8250.45% up from last year.
  • Per Atara Biotherapeutics' latest filing, its EPS (Basic) stood at -$0.32 for Q3 2025, which was up 8907.85% from $0.2 recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' EPS (Basic) ranged from a high of $3.53 in Q1 2025 and a low of -$16.91 during Q2 2023
  • For the 4-year period, Atara Biotherapeutics' EPS (Basic) averaged around -$4.01, with its median value being -$0.87 (2022).
  • As far as peak fluctuations go, Atara Biotherapeutics' EPS (Basic) crashed by 949444.44% in 2023, and later surged by 16249.94% in 2025.
  • Atara Biotherapeutics' EPS (Basic) (Quarter) stood at -$0.73 in 2022, then crashed by 1806.85% to -$13.92 in 2023, then skyrocketed by 87.82% to -$1.7 in 2024, then surged by 81.12% to -$0.32 in 2025.
  • Its EPS (Basic) was -$0.32 in Q3 2025, compared to $0.2 in Q2 2025 and $3.53 in Q1 2025.